Home >> Industry News >> Microbix expands pandemic test controls portfolio

Microbix expands pandemic test controls portfolio

image_pdfCreate PDF

Nov. 22, 2021—Microbix Biosystems has expanded its portfolio of Quality Assessment Products to include controls that support PCR tests for four major variants of concern of SARS-CoV-2.

The company says it has developed and is commercializing IVD quality controls to support workflow accuracy of clinical laboratory PCR tests for the Brazilian (P.1), delta (B.1.617), South African (B.1.351), and U.K. (B.1.1.7) VOCs, in addition to QAPs for the Wuhan strain of the virus. The controls are made using Copan FLOQSwabs and have a room temperature stability of 12 months.

CAP TODAY
X